WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO is funded by the Walloon Region. Our mission is to support strategic fundamental research through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications in all fields of biotechnology.
Publication in Cell Reports: A research team led by Cédric Blanpain, WELBIO investigator at the Université Libre de Bruxelles uncovers the importance of tumor plasticity for cancer metastasis. They provide evidence that tumor cells undergo epithelial to mesenchymal transition during the metastatic process initiation, and mesenchymal to epithelial transition also at the metastatic site.
Decio L. Eizirik, Welbio researcher at the ULB Center for Diabetes Research, Universite Libre de Bruxelles, and his co-workers clarified the role for pancreatic beta cells in type 1 diabetes. This work provides an explanation for the reasons behind the immune system targeting beta cells under special conditions. This study is published in Nature Genetics.
Thomas Marichal (WELBIO and ERC investigator, FRS-FNRS Research Associate) and his team identified a key role of RABGEF1 protein in the regulation of intestinal inflammation by epithelial cells. This study is published in Mucosal Immunology.